Peptide Comparison
SLU-PP-332vsXenin-25
A groundbreaking exercise mimetic compound that tricks your body into thinking it's training for a marathon—boosting metabolism, burning fat, and building endurance without you ever having to hit the gym.
The Natural Incretin Helper Peptide That Enhances Glucose Control and Insulin Response
At a Glance
Quick
comparison
Dose Range
SLU-PP-332
250–1500 mcg
Xenin-25
0.1 nmol/kg–1.0 nmol/kg nmol/kg
Frequency
SLU-PP-332
Once daily
Xenin-25
Once daily
Administration
SLU-PP-332
Oral
Xenin-25
Intravenous (IV)
Cycle Length
SLU-PP-332
8-12 weeks
Xenin-25
Ongoing/indefinite
Onset Speed
SLU-PP-332
Moderate (1-2 weeks)
Xenin-25
Moderate (1-2 weeks)
Evidence Level
SLU-PP-332
Strong preclinical (extensive animal studies)
Xenin-25
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Metabolic Enhancement
Exercise Mimetic
Fat Loss Support
Glucose Control & Insulin Response
Metabolic Synergy
Natural Physiological Action
Technical Data
Compound
specifications
SLU-PP-332
Molecular Formula
C18H14N2O2
Molecular Weight
290.3 g/mol
Half-Life
Estimated 4-8 hours
Bioavailability
Moderate (oral); High (injection)
CAS Number
863971-53-5
Xenin-25
Molecular Formula
C139H224N38O32S
Molecular Weight
2971.6 g/mol
Half-Life
10-15 minutes (IV administration, subject to variation)
Bioavailability
IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide nature (active research)
CAS Number
Not available
Protocols
Dosing
tiers
SLU-PP-332
Xenin-25
Applications
Best
suited for
SLU-PP-332
Metabolic Syndrome Warriors
If you're battling the frustrating combination of belly fat, blood sugar issues, and sluggish metabolism, SLU-PP-332 targets the exact pathways that go haywire in metabolic syndrome. It's like giving your metabolism a personal trainer that works 24/7.
Exercise-Limited Individuals
Injuries, disabilities, or conditions that prevent normal exercise don't have to mean giving up on metabolic health. SLU-PP-332 activates exercise pathways even when you can't hit the gym, potentially maintaining metabolic function during recovery periods.
Endurance Athletes Seeking an Edge
For those already training hard, SLU-PP-332 may amplify your body's natural adaptation to exercise. Research shows it synergizes with actual training, potentially helping you get more benefit from every workout.
Aging Adults Fighting Metabolic Decline
As we age, our mitochondria become less efficient and our metabolism slows. SLU-PP-332 targets the ERR receptors that control mitochondrial function, potentially helping maintain youthful metabolic capacity even as birthdays add up.
Xenin-25
Supporting healthy glucose metabolism
Xenin-25 is particularly well-suited for individuals focused on supporting healthy glucose metabolism. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing insulin response efficiency
Xenin-25 is particularly well-suited for individuals focused on enhancing insulin response efficiency. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into metabolic disorder treatment
Xenin-25 is particularly well-suited for individuals focused on research into metabolic disorder treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
SLU-PP-332
Common
- Mild GI discomfort
- Increased energy
- Mild warmth or temperature increase
Uncommon
- Changes in appetite
- Mild headache
Serious
- Allergic reaction
Xenin-25
Common
- Gastrointestinal Discomfort
- Nausea
- Headache
Uncommon
- Injection Site Reactions
- Mild Fatigue
Serious
- Hypoglycemia Risk
Research Status
Safety
& evidence
SLU-PP-332
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
SLU-PP-332 has demonstrated a favorable safety profile in extensive preclinical studies. Mouse studies showed no severe adverse events even at relatively high doses, with researchers noting improvements in metabolic markers without negative effects on appetite, behavior, or organ function. The compound appears well-tolerated in animal models, though human clinical trials are still needed to fully establish its safety profile in people.
Contraindications
- xPregnancy or planning to become pregnant
- xCurrently breastfeeding
- xKnown allergy to the compound or similar chemicals
- xChildren and adolescents
- xSevere liver or kidney disease
Xenin-25
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials. The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common. Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents. Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use. The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.
Contraindications
- xMedullary thyroid carcinoma or personal/family history
- xMultiple endocrine neoplasia type 2
- xPregnancy and breastfeeding
- xSevere kidney or liver disease
Decision Guide
Which is
right for you?
Choose SLU-PP-332 if...
- Enhanced metabolic health
- Fat loss without extreme dieting
- Improved exercise endurance
- Supporting mitochondrial function
Choose Xenin-25 if...
- Supporting healthy glucose metabolism
- Enhancing insulin response efficiency
- Research into metabolic disorder treatment